论文部分内容阅读
目的评价珠子肝泰胶囊联合阿德福韦酯治疗慢性乙型肝炎的安全性和疗效。方法选择200例慢性乙型肝炎患者,随机分成试验组(A组)和对照组(B组),评价珠子肝泰胶囊联合阿德福韦酯(A组)与单用阿德福韦酯(B组)治疗慢性乙型肝炎的安全性和疗效。结果A组患者在治疗12周时发生肝功能改善、ALT复常;增强抗HBV作用,快速抑制HBV DNA;在这两方面A组明显优于B组(P均<0.05)。但12周时两组在血清HBV DNA转阴率、HBeAg阴转率等方面比较无统计学差异。结论珠子肝泰胶囊联合阿德福韦酯治疗慢性乙型肝炎患者,在ALT复常、快速抑制HBV DNA方面都显示了较好的临床疗效。
Objective To evaluate the safety and efficacy of Beizhigan Tai capsule combined with adefovir dipivoxil in the treatment of chronic hepatitis B. Methods A total of 200 patients with chronic hepatitis B were selected and randomly divided into experimental group (group A) and control group (group B). The effects of Beizhegantai capsule combined with adefovir dipivoxil (group A) and adefovir dipivoxil alone B group) in the treatment of chronic hepatitis B safety and efficacy. Results A group of patients in the treatment of 12 weeks of liver function improved, ALT normal; enhanced anti-HBV effect, rapid inhibition of HBV DNA; in both groups A group was significantly better than the B group (P all <0.05). However, there was no significant difference between the two groups in serum HBV DNA negative rate and HBeAg negative rate at 12 weeks. Conclusion Beizheigantai combined with adefovir dipivoxil treatment of chronic hepatitis B patients, ALT normalization, rapid inhibition of HBV DNA showed good clinical efficacy.